Life-threatening dermatoses due to connective tissue disorders

Clinics in Dermatology

Volumn 23, Issue 3, 2005, Pages 238-248

  Katsambas, Andreas ^a   Stefanaki, Christina ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

3 E10; ABETIMUS; ALUMINUM CHLORIDE; ANTIMALARIAL AGENT; AZATHIOPRINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CHLORAMBUCIL; CISAPRIDE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; ETANERCEPT; ILOPROST; IMMUNOGLOBULIN; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; MEPREDNISONE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; OMEPRAZOLE; PENICILLAMINE; PREDNISOLONE; PREDNISONE; PROBENECID; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTANOID; PROTON PUMP INHIBITOR; RELAXIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNIPROST; VASODILATOR AGENT; WARFARIN;

AUTOIMMUNE DISEASE; CALCINOSIS; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE COURSE; HEART ARRHYTHMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

EID: 19444368087     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2004.06.004     Document Type: Article

References (155)

1. M.D. Mayes Classification and epidemiology of scleroderma Semin. Cutan. Med. Surg. 17 1998 22 26
2. M.D. Mayes Scleroderma epidemiology Rheum. Dis. Clin. North Am. 29 2003 239 254
3. F.K. Tan Systemic sclerosis: the susceptible host (genetics and environment) Rheum. Dis. Clin. North Am. 29 2003 211 237
4. T. Kawakami, H. Ihn, and W. Xu Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype J. Invest. Dermatol. 110 1998 47 51
5. A. McWhirter, P. Colosetti, and K. Rubin Collagen type I is not under autocrine control by transforming factor beta 1 in normal and scleroderma fibroblasts Lab. Invest. 71 1994 885 894
6. C. Dong, S. Zhu, and T. Wang Deficient Smad7 expression: a putative molecular defect in scleroderma Proc. Natl. Acad. Sci. U. S. A. 99 2002 3908 3913
7. A.K. Ghosh, W. Yuan, and Y. Mori Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators J. Biol. Chem. 276 2001 11041 11048
8. K. Takehara Pathogenesis of systemic sclerosis J. Rheumatol. 30 2003 755 759
9. N. Yazawa, K. Kikuchi, and H. Ihn Serum levels of tissue inhibitor of metalloproteinase 2 in patients with systemic sclerosis J. Am. Acad. Dermatol. 42 2000 70 75
10. S.A. Young-Min, C. Beeton, and R. Laughton Serum TIMP-1, TIMP-2 and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon and in normal controls Ann. Rheum. Dis. 60 2001 846 851
11. K. Yamane, T. Miyauchi, and N. Suzuki Significance of plasma endothelin-1 in patients with systemic sclerosis J. Rheumatol. 19 1992 1566 1571
12. D. Carvalho, C.O. Savage, and C.M. Black IgG anti-endothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines J. Clin. Invest. 97 1996 111 119
13. M.B. Kahaleh, P.S. Fan, and T. Otsuka Gammadelta receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro Clin. Immunol. 91 1999 188 195
14. Y. Renaudineau, E. Grunebeaum, and I. Krause Anti-endothelial cell antibodies (AECA) in systemic sclerosis-increased sensitivity using different endothelial cell substrates and association with other autoantibodies Autoimmunity 33 2001 171 179
15. T.A. Medsger Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status and psychologic well-being Rheum. Dis. Clin. North Am. 29 2003 255 273
16. V.D. Steen, and T.A. Medsger Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma Arthritis Rheum. 43 2000 2437 2444
17. V.D. Steen, and T.A. Medsger Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival Arthritis Rheum. 44 2001 2828 2835
18. S. Jacobsen, S. Ullman, and G.Q. Shen Influence of clinical features, serum antinuclear antibodies and lung function on survival of patients with systemic sclerosis J. Rheumatol. 28 2001 2454 2459
19. S. Jablonska, and M. Blaszczyk Scleroderma: what is the reason for the death? J. Eur. Acad. Dermatol. Venereol. 16 2002 557 558
20. J.H. Talbott, and M. Barrocas Progressive systemic sclerosis (PSS) and malignancy, pulmonary and non-pulmonary Medicine 58 1979 182 207
21. C.P. Simenon, L. Armadans, and V. Fonollosa Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis Ann. Rheum. Dis. 56 1997 723 728
22. R. Hesselstrand, A. Scheja, and A. Akeson Mortality and causes of death in a Swedish series of systemic sclerosis patients Ann. Rheum. Dis. 57 1998 682 686
23. M. Matucci-Cerinic, S. D'Angelo, and C.P. Denton Assessment of lung involvement Clin. Exp. Rheumatol. 21 2003 S19 S23
24. B. White Interstitial lung disease in scleroderma Rheum. Dis. Clin. North Am. 29 2003 371 390
25. V.D. Steen, C. Conte, and G.R. Owens Severe restrictive lung disease in systemic sclerosis Arthritis Rheum. 37 1994 1283 1289
26. N.J. McHugh, O. Distler, and R. Giacomelli Non organ based markers in systemic sclerosis Clin. Exp. Rheumatol. 21 2003 S32 S38
27. S. Shinichi, T. Nagaoka, and M. Hasegawa Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extend of skin sclerosis and severity of pulmonary fibrosis J. Rheumatol. 27 2000 149 154
28. S. Sato, T. Nagaoka, and M. Hasegawa Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis Dermatology 200 2000 196 201
29. H. Takahashi, Y. Kuroki, and H. Tanaka Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis Am. J. Respir. Crit. Care Med. 162 2000 258 263
30. A.N. Sapadin, and R. Fleischmajer Treatment of scleroderma Arch. Dermatol. 138 2002 99 105
31. E.M. Silver, J.H. Warrick, and M.B. Kinsella Cyclophosphamide and low dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease J. Rheumatol. 20 1993 838 844
32. B. White, W. Moore, and F. Wingley Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann. Intern. Med. 132 2000 947 954
33. I. Pakas, J.P. Ioannides, and K. Malagari Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease J. Rheumatol. 29 2002 298 304
34. C.M. Black, A.J. Silman, and A.I. Herrick Interferon-alpha does not improve outcome at one year in patients with diffuse scleroderma: results of a randomized, double blind, placebo controlled trial Arthritis Rheum. 42 1999 299 305
35. P.J. Clements, D.E. Furst, and W.K. Wong High dose versus low dose penicillamine in early diffuse systemic sclerosis: analysis of a two year, double blind, randomized controlled clinical trial Arthritis Rheum. 42 1999 1194 1203
36. F.H. Van der Hogen, A.M. Boerbooms, and A.J. Swaak Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double blind trial followed by a 24 hour week observational trial Br. J. Rheumatol. 35 1996 364 372
37. J. Pope, N. Bellamy, and J. Seibold A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma Arthritis Rheum. 44 2001 1351 1358
38. A.H. Rock, B. Freunflich, and B.V. Jegasothy Treatment of systemic sclerosis with extracorporeal photochemotherapy: results of a multicenter trial Arch. Dermatol. 128 1992 337 346
39. M.H. Elman, P.A. McDonald, and F.A. Hayes Etanercept as treatment for diffuse scleroderma: a pilot study Arthritis Rheum. 43 2000 S392
40. H.D. Sinclair, J.D. Williams, and M.A. Rahman Clinical efficacy of antithymocyte globulin in systemic sclerosis: results of a placebo controlled trial Arthritis Rheum. 36 1994 s217
41. J.R. Seibold, J.H. Korn, and P.J. Clements Recombinant human relaxin in the treatment of scleroderma: a randomized double-blind, placebo controlled trial Ann. Intern. Med. 132 2000 871 879
42. K.M. McKown, L.D. Carbone, and J. Bustillo Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen Arthritis Rheum. 43 2000 1054 1061
43. P.J. Clements, and D.E. Furts Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation J. Rheumatol. 24 1997 S85 S88
44. M. Binks, J.R. Passweg, and D. Furst Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease Ann. Rheum. Dis. 60 2001 577 584
45. L. Schachna, F.M. Wingley, and B. White Lung transplantation in scleroderma: the John Hopkins experience Arthritis Rheum. 43 2000 S392
46. A. Righi, and M.M. Cerinic New treatments in scleroderma: the rheumatologic perspective J. Eur. Acad. Dermatol. Venereol. 16 2002 431 432
47. C.P. Denton, and C.M. Black Pulmonary hypertension in systemic sclerosis Rheum. Dis. Clin. North Am. 29 2003 335 349
48. E.T. Koh, P. Lee, and D.D. Gladman Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients Br. J. Rheumatol. 35 1996 989 993
49. A.J. MacGregor, R. Canavan, and C. Knight Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival Rheumatology 40 2001 453 459
50. D. Wax, R. Garofano, and R.J. Barst Effects of long-term infusion of prostacyclin on exercise performance in patients with pulmonary hypertension Chest 116 1999 914 920
51. J. De la Mata, M.A. Gomez-Sanchez, M. Arazana, and J.J. Gomez-Reino Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases Arthritis Rheum. 37 1994 1528 1533
52. J.J. Belch, H.A. Capell, and E.D. Cooke Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study Ann. Rheum. Dis. 54 1995 197 200
53. D.B. Badesch, V.F. Tapson, and M.D. McCoon Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. A randomized controlled trial Ann. Intern. Med. 132 2000 425 434
54. G. Simonneau, R.J. Barst, and N. Galie Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double blind, randomized, placebo controlled trial Am. J. Respir. Crit. Care Med. 165 2002 800 804
55. R.N. Channick, G. Simonnea, and O. Sitbon Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study Lancet 358 2001 1119 1123
56. L.F. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary hypertension N. Engl. J. Med. 346 2002 896 903
57. V.D. Steen, M.D. Mayes, and P.A. Merkel Assessment of kidney involvement Clin. Exp. Rheumatol. 21 2003 S29 S31
58. V.D. Steen Scleroderma renal crisis Rheum. Dis. Clin. North Am. 29 2003 315 333
59. V.D. Steen, and T.A. Medsger Jr. Long term outcomes of scleroderma renal crisis Ann. Intern. Med. 17 2000 600 603
60. C. Ferri, M. Emdin, H. Nielsen, and P. Bruhlmann Assessment of heart involvement Clin. Exp. Rheumatol. 21 2003 S24 S28
61. T.A. Medsger, S. Bombardieri, and L. Czirjak Assessment of disease severity and prognosis Clin. Exp. Rheumatol. 21 2003 S42 S46
62. M. Paradiso, M. Di Franco, and A. Musca Ventricular late potentials in systemic sclerosis: relationship with skin involvement J. Rheumatol. 29 2002 1388 1392
63. R.W. Sjogren Review: gastrointestinal disorders in scleroderma Arthritis Rheum. 37 1994 1265 1282
64. P.J. Clements, R. Bevcar, and A.A. Drosos Assessment of gastrointestinal involvement Clin. Exp. Rheumatol. 21 2003 S15 S18
65. J.H. Stone, and F.M. Wigley Management of systemic sclerosis: the art and science Semin. Cutan. Med. Surg. 17 1998 55 64
66. L.A. Dourmishev, A.L. Dourmishev, and R.A. Schwartz Dermatomyositis: cutaneous manifestations of its variants Int. J. Dermatol. 41 2002 625 630
67. I. Caro Dermatomyositis Semin. Cutan. Med. Surg. 20 2001 38 45
68. R.D. Sontheimer Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis Curr. Opin. Rheumatol. 11 1999 475 482
69. A. Reed, and S.R. Yttenberg Genetic and environmental risk factors for idiopathic inflammatory myopathies Rheum. Dis. Clin. North Am. 28 2002 891 916
70. S.O. Kovacs, and C.S. Kovacs Dermatomyositis J. Am. Acad. Dermatol. 39 1998 899 920
71. J. Callen Dermatomyositis Lancet 355 2000 53 57
72. Y. Yazici, and L.J. Kagen Clinical presentation of the idiopathic inflammatory myopathies Rheum. Dis. Clin. North Am. 28 2002 823 832
73. L.M. Pachman Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression Rheum. Dis. Clin. North Am. 28 2002 579 602
74. R.D. Sontheimer Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects Dermatol. Clin. 20 2002 387 408
75. I. Marie, E. Hachulla, and P.Y. Hantron Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis J. Rheumatol. 28 2001 2230 2237
76. A.V. Ramanan, and B.M. Feldman Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes Rheum. Dis. Clin. North Am. 28 2002 833 857
77. I.N. Targoff Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies Rheum. Dis. Clin. North Am. 28 2002 859 890
78. T.L. Jansen, P. Barrera, and B.G. Van Engelen Dermatomyositis with subclinical myositis and spontaneous pneumo-mediastinum with pneumothorax: case report and review of the literature Clin. Exp. Rheumatol. 16 1998 733 735
79. C.R. Maoz, P. Langevitz, and A. Livneh High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11 year analysis Semin. Arthritis Rheum. 27 1998 319 324
80. R.E. Hunger, C. Durr, and C.U. Brand Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy Dermatology 202 2001 123 126
81. M.A. Dawkins, J.L. Jorizzo, and F.O. Walker Dermatomyositis: a dermatology based case series J. Am. Acad. Dermatol. 38 1998 397 404
82. C.V. Oddis, and T.A. Medsger Jr. Polymyositis-dermatomyositis N. Bellamy Prognosis in the rheumatic diseases 1991 Kluwer Academic Publishers Lancaster (UK) 233 239
83. C.V. Oddis Idiopathic inflammatory myopathy: management and prognosis Rheum. Dis. Clin. North Am. 28 2002 979 1001
84. M.F.G. Van der Meulen, J.E. Hoogendijk, and J.H.J. Wokke Oral pulsed high-dose dexamethasone for myositis J. Neurol. 247 2000 102 105
85. L. Villalba, and E.M. Adams Update on therapy for refractory dermatomyositis and polymyositis Curr. Opin. Rheumatol. 8 1996 544 551
86. M.M. Joffe, L.A. Love, and R.L. Leff Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy Am. J. Med. 94 1993 379 387
87. T.W. Bunch Prednisolone and azathioprine for polymyositis: long-term follow up Arthritis Rheum. 24 1981 45 48
88. L. Villalba, J.E. Hicks, and E.M. Adams Treatment of refractory myositis: a randomized crossover study of two new toxic regimens Arthritis Rheum. 41 1998 392 399
89. K. Maeda, R. Kimura, and K. Komuta Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand. J. Rheumatol. 26 1997 24 29
90. Y. Nawata, K. Kurasawa, and K. Takabayashi Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine J. Rheumatol. 26 1999 1527 1533
91. A. Sauty, T. Rochat, and O.D. Schoch Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies Eur. Respir. J. 10 1997 2907 2912
92. C.V. Oddis, F.C. Sciurba, and K.A. Elmag Tacrolimus in refractory polymyositis with interstitial lung disease Lancet 353 1999 1762 1763
93. A. Schnabel, M. Reuter, and W.L. Gross Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases Arthritis Rheum. 41 1998 1215 1220
94. S. Bombardieri, G.R.V. Hughes, and R. Neri Cyclophosphamide in severe polymyositis Lancet 1 1988 1138 1139
95. M.C. Dalakas Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis Neurology 51 1998 S37 S45
96. A. Rutter, and T.A. Luger High dose intravenous immunoglobulins: an approach to treat severe immune mediated and autoimmune diseases of the skin J. Am. Acad. Dermatol. 44 2001 1010 1024
97. I. Marie, E. Hachulla, and H. Levesque Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis J. Rheumatol. 26 1999 2706 2709
98. T.Y. Woo, J.P. Callen, and J.J. Voorhees Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine J. Am. Acad. Dermatol. 10 1984 592 600
99. J.S. Kasteler, and J.P. Callen Low dose methotrexate administered weekly is an effective corticoid sparing agent for the treatment of cutaneous manifestations of dermatomyositis J. Am. Acad. Dermatol. 36 1997 67 71
100. A.C. Geiber, H.C. Nousari, and F.M. Wigley Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases J. Rheumatol. 27 2000 1542 1545
101. M. Ueda, R. Makinodan, M. Matsumura, and M. Ichihashi Successful treatment of amyopathic dermatomyositis with topical tacrolimus Br. J. Dermatol. 148 2003 595 596
102. S. Bingham, B. Griffiths, and D. McGonagle Autologous stem cell transplantation for rapidly progressive Jo-1 positive polymyositis and long-term follow up Br. J. Haematol. 113 2001 840 841
103. A. Nzeusseu, P. Durez, F. Houssiau, and J. Devogelaer Successful use of infliximab in a case of refractory juvenile dermatomyositis Arthritis Rheum. 44 2001 S90
104. J.B. Harley, K.L. Moser, and P.M. Gaffney The genetics of human systemic lupus erythematosus Curr. Opin. Immunol. 10 1998 690
105. K.E. Sullivan Genetics of systemic lupus erythematosus Rheum. Dis. Clin. North Am. 26 2000 229 255
106. F. Andrade, L. Casciola-Rosen, and A. Rosen Apoptosis in systemic lupus erythematosus Rheum. Dis. Clin. North Am. 26 2000 215 227
107. P. Patel, and V. Werth Cutaneous lupus erythematosus: a review Dermatol. Clin. 20 2002 373 385
108. M. Petri Hopkins lupus cohort. 1999 Update Rheum. Dis. Clin. North Am. 26 2000 199 213
109. J.N. Gilliam The cutaneous signs of lupus erythematosus Contin. Educ. Fam. Phys. 6 1977 34 70
110. J.A. Yell, J. Mbuagbaw, and S.M. Burge Cutaneous manifestations of systemic lupus erythematosus Br. J. Dermatol. 135 1996 355 362
111. D.P. McCauliffe Cutaneous lupus erythematosus Semin. Cutan. Med. Surg. 20 2001 14 26
112. E. Chlebus, H. Wolska, M. Blaszczyk, and S. Jablonska Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications J. Am. Acad. Dermatol. 38 1998 405 412
113. R.D. Brasington, L.E. Kahl, and P. Ranganathan Immunologic rheumatic disorders J. Allergy Clin. Immunol. 111 2003 S593 S601
114. B. Tebbe, and C.E. Orfanos Epidemiology and socioeconomic impact of skin disease in lupus erythematosus Lupus 6 1997 96 104
115. M. Juarez, R. Misischia, and G.S. Alarcon Infections in systemic lupus erythematosus, scleroderma and polymyositis/dermatomyositis Rheum. Dis. Clin. North Am. 29 2003 163 184
116. R. Cervera, M.A. Khamashta, and J. Font Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1000 patients Medicine 78 1999 167 175
117. M. Abu-Shakra, M.B. Urowitz, D.D. Gladman, and J. Gough Mortality studies in systemic lupus erythematosus. Results from a single center: I. Causes of death J. Rheumatol. 22 1995 1259 1264
118. J.F. Fries, S. Weyl, and H.R. Hellman Estimating prognosis in disease activity Am. J. Med. 57 1974 561 566
119. M.J. Seleznick, and J.F. Fries Variables associated with decreased survival in systemic lupus erythematosus Semin. Arthritis Rheum. 21 1991 73 80
120. G.S. Alarcon, G. McGwin, and H.M. Bastian Systemic lupus erythematosus in three ethnic groups VIII. Predictors of early mortality in the LUMINA cohort Arthritis Care Res. 45 2001 191 202
121. J. Golbus, and W.J. McCune Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment Rheum. Dis. Clin. North Am. 20 1994 213 242
122. E.M. Ginzler, D.T. Felson, J.M. Anthony, and J.J. Anderson Hypertension increases the risk of renal deterioration in systemic lupus erythematosus J. Rheumatol. 20 1993 1694 1700
123. D.T. Boumpas, H.A. Austin, and B.J. Fessler Systemic lupus erythematosus: emerging concepts: Part I. Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease Ann. Intern. Med. 122 1995 940 950
124. R.L. Brey, and A. Escalante Neurological manifestations of antiphospholipid antibody syndrome Lupus 7 1998 S67
125. Y. Takashi Livedo reticularis and central nervous system involvement in systemic lupus erythematosus Arch. Dermatol. 122 1986 66 70
126. M.C. Amigo, and M.A. Khamashta Antiphospholipid syndrome in systemic lupus erythematosus Rheum. Dis. Clin. North Am. 26 2000 331 348
127. M. Petri, D. Spence, L.R. Bone, and M.C. Hochberg Coronary artery disease risk factors in the John Hopkins lupus cohort: prevalence, recognition by patients and prevention practices Medicine 71 1992 291 302
128. J.D. Reveille, A. Bartolucci, and G.S. Alarcon Prognosis in systemic lupus erythematosus: negative impact of increasing age at onset, black race, and thrombocytopenia as well as causes of death Arthritis Rheum. 33 1990 37 48
129. I.N. Bruce, D.D. Gladman, and M.B. Urowitz Premature atherosclerosis in systemic lupus erythematosus Rheum. Dis. Clin. North Am. 26 2000 257 278
130. H.P. Wiedmann, and R.A. Matthay Pulmonary manifestations of systemic lupus erythematosus J. Thorac. Imag. 7 1992 1 18
131. D. Mulherin, and B. Bresnihan Systemic lupus erythematosus Clin. Rheumatol. 7 1994 31 57
132. E.P. Schwab, H.R. Schumacher Jr., B. Freundlich, and P.E. Callegari Pulmonary alveolar hemorrhage in systemic lupus erythematosus Semin. Arthritis Rheum. 23 1993 8 15
133. R.A. Asherson, T.W. Higenbottam, and A.T. Dihn Xuan Pulmonary hypertension in a lupus clinic: experience with twenty four patients J. Rheumatol. 17 1990 1292 1298
134. R.A. Asherson, and C.M. Oakley Pulmonary hypertension and systemic lupus erythematosus J. Rheumatol. 13 1986 1 5
135. B. Tebbe, U. Mansman, and U. Wollina Markers in cutaneous lupus erythematosus indicating systemic involvement: a multicenter study on 296 patients Acta. Derm. Venereol. 77 1997 305 308
136. C. Lanigne, F. Maillot, and L. Machet Lethal pancytopenia associated with chilblain lupus erythematosus Acta. Derm. Venereol. 80 2001 393
137. J. Wenzel, R. Bauer, and M. Uerlich The value of lymphocytopenia as a marker of systemic involvement in cutaneous lupus erythematosus Br. J. Dermatol. 146 2002 869 871
138. C. Cardinali, M. Caproni, and P. Fabbri The utility of the lupus band test on sun-protected non-lesional skin for the diagnosis of systemic lupus erythematosus Clin. Exp. Rheumatol. 17 1999 427 432
139. D.R. Black, C.A. Hornung, P.D. Schneider, and J.P. Callen Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus Arch. Dermatol. 138 2002 1175 1178
140. M.P. Heffernan, J.H. Do, and J. Mehta Antinuclear antibodies in dermatology Semin. Cutan. Med. Surg. 20 2001 2 13
141. R.A. Ortmann, and J.H. Klippel Update on cyclophosphamide for systemic lupus erythematosus Rheum. Dis. Clin. North Am. 26 2000 363 375
142. R.P. Kimberly, M.D. Lockshin, and R.L. Sherman High dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus Am. J. Med. 70 1981 817 824
143. C.G. Mackworth-Young, J. David, S.H. Morgan, and G.R. Hughs A double blind placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus Ann. Rheum. Dis. 47 1988 496 502
144. A.R. Eiser, and H.M. Shanies Treatment of lupus interstitial lung disease with intravenous cyclophosphamide Arthritis Rheum. 37 1994 428 431
145. A. Schnabel, M. Reuter, and W.L. Gross Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases Arthritis Rheum. 41 1998 1215 1220
146. R.A. Brodsky, M. Petri, and B.D. Smith Immunoablative high dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease Ann. Intern. Med. 129 1998 1031 1035
147. H. Favre, P.A. Miescher, and Y.P. Huang Cyclosporine in the treatment of lupus nephritis Am. J. Nephrol. 9 1989 S57 S60
148. M. Tokuda, N. Kurata, and A. Mizogushi Effect of low-dose cyclosporine A on systemic lupus erythematosus disease activity Arthritis Rheum. 37 1994 551 558
149. W.A. Briggs, M.J. Choi, and P.J. Scheel Successful mofetil treatment of glomerular disease Am. J. Kidney. Dis. 31 1998 213 217
150. A. Ho, L. Madger, and M. Petri The effect of azathioprine/mycophenolate on systemic lupus erythematosus activity Arthritis Rheum. 41 1998 S281
151. N. Pashinian, D.J. Wallace, and J.R. Klinenberg Mycophenolate mofetil for systemic lupus erythematosus Arthritis Rheum. 41 1998 S110
152. G. Moroni, M. Maccario, and G. Banfi Treatment of membranous lupus nephritis Am. J. Kidney. Dis. 31 1998 681 686
153. V. Strand New therapies for systemic lupus erythematosus Rheum. Dis. Clin. North Am. 26 2000 389 406
154. A.M. Marmont Stem cell transplantation for severe autoimmune diseases: progress and problems Haematologica 83 1998 733 734
155. R.A. Brodsky, M. Petri, and R.J. Jones Hematopoietic stem cell transplantation for systemic lupus erythematosus Rheum. Dis. Clin. North Am. 26 2000 377 387